Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17555496 | 0.80 | CHRNB2 (0.44) | MAPT | |
| SCHEMBL18439119 | 0.77 | TDO2 (0.56) | MAPTCYP11B1CYP11B2CYP1A2CYP3A4 | |
| SCHEMBL17556326 | 0.77 | ABL1 (0.44) | CYP1A1CYP1B1GAAMAPTLRRK2 | |
| SCHEMBL17555475 | 0.76 | CA12 (0.39) | KDM1ACYP11B1CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL17555511 | 0.75 | LTA4H (0.44) | HRH3 | |
| SCHEMBL15301520 | 0.75 | CYP11B2 (0.39) | CYP11B1CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL15650052 | 0.74 | LRRK2 (0.41) | CYP1A1CYP1B1GAAMAPTLRRK2 | |
| SCHEMBL15371475 | 0.72 | TLR7 (0.36) | — | |
| SCHEMBL1337757 | 0.72 | KDM1A (0.40) | CYP1A1CYP1B1GAAMAPTLRRK2 | |
| SCHEMBL17555617 | 0.72 | FYN (0.44) | CYP1A1CYP1B1GAAMAPTLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188634-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10188634-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10052331-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180221354-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-20180221354-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-20180221354-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-20180177787-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-06-28 | — | — | US | disclosed |
| US-20180177787-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-06-28 | — | — | US | disclosed |
| US-20180177787-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-06-28 | — | — | US | disclosed |
| US-9763951-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170216299-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2017-08-03 | — | — | US | disclosed |
| WO-2017023988-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023988-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-9475825-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475825-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475825-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| WO-2016040188-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177787-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | CYP1A1 1876/4885CYP1B1 1175/4885GAA 3396/4885 |
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | CYP1A1 1876/4885CYP1B1 1175/4885GAA 3396/4885 |
| US-20180221354-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT3, WNT3A, WNT1 | CYP1A1 1696/4885CYP1B1 664/4885GAA 3409/4885 |
| US-10188634-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | CYP1A1 1501/4885CYP1B1 629/4885GAA 3360/4885 |
| US-20170216299-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | CYP1A1 1876/4885CYP1B1 1175/4885GAA 3396/4885 |
| US-10052331-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | WNT3, WNT1, WNT3A | CYP1A1 1876/4885CYP1B1 1175/4885GAA 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.